{
    "nctId": "NCT05236387",
    "briefTitle": "Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection",
    "officialTitle": "A Single-Center, Open-Label Study Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Percentage of clipped nodes detected with 99m Tc-Tm intraoperatively as determined with a hand held gamma detection device",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. The patient has provided written informed consent with HIPAA authorization.\n2. The patient is female or male and \u226518 years of age at the time of consent.\n3. The patient has been diagnosed with invasive Stage 2-3 breast cancer (T1-3; N1-2).\n4. The patient has no history of inflammatory breast cancer.\n5. The patient has no matted node on examination (N3).\n6. The patient is eligible for neoadjuvant chemotherapy (NAC).\n7. The patient is a candidate for surgical intervention, with sentinel lymph node assessment being a part of the surgical plan.\n8. If of childbearing potential, the patient has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.\n9. The patient has no known allergies or hypersensitivity to 99mTc-TM, BD, or India ink.\n\nExclusion Criteria:\n\n1. The patient is pregnant or lactating.\n2. The patient has clinical and/or radiological evidence of metastatic or systemic disease. Oligo metastatic disease is acceptable (one organ and controlled).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}